Antisense modulation of BCL-X expression
US6172216A · kind A · utility
215Cited by
7References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 1998 |
| Grant date | Jan 9, 2001 |
| Priority date | — |
| Expiry date | Oct 7, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.